Australia markets open in 6 hours 20 minutes
  • ALL ORDS

    7,339.30
    -52.40 (-0.71%)
     
  • AUD/USD

    0.7092
    +0.0004 (+0.05%)
     
  • ASX 200

    7,105.90
    -49.30 (-0.69%)
     
  • OIL

    114.21
    +3.88 (+3.52%)
     
  • GOLD

    1,847.80
    +1.50 (+0.08%)
     
  • BTC-AUD

    41,686.93
    -437.78 (-1.04%)
     
  • CMC Crypto 200

    648.51
    -12.63 (-1.91%)
     

Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a panel discussion during the LifeSci Partners 11th Annual Corporate Access Event.

Details for the panel discussions are below:

Title:

Patient Advocacy: Honing the Skill for Crossover Communications between Patients and Stakeholders

Date:

Thursday, January 6, 2022

Time:

2:00 PM ET

Webcast:

https://wsw.com/webcast/lifesci3/panel10/2456850

A live audio webcast and replay of the panel discussion will be available in the Investors section on the Company’s website at www.soleno.life.

Members of Soleno’s management team will also be conducting one-on-one meetings with institutional investors during the event.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting